Form 4: Korro Bio, Inc. Executive Oliver Dolan Reports Stock Option Grant

Oliver Dolan, Senior Vice President of Finance at Korro Bio, Inc., reports the acquisition of stock options for 20,000 shares on April 1, 2025.

Summary

• On April 1, 2025, Oliver Dolan, Senior Vice President of Finance at Korro Bio, Inc., filed a Form 4.
• The filing reports the grant of stock options to Dolan, allowing him to purchase 20,000 shares of Korro Bio's common stock at an exercise price of $15.95 per share.
• The options vest in 48 equal monthly installments starting March 27, 2025, contingent upon Dolan's continued service.
• The options expire on March 26, 2035.
• Following the reported transaction, Dolan directly owns derivative securities for 20,000 shares.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, indicating stability and alignment of interests. It's a neutral-positive event.

Positives

• The grant of stock options to a key executive aligns their interests with the long-term success of the company.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to incentivize performance and retain key personnel. This grant aligns with standard practices for companies like Korro Bio.

Comparison to Industry Standards

• Stock option grants are a typical component of compensation packages for executives in biotech companies.
• Companies like Moderna and BioNTech also use stock options to incentivize their leadership teams.
• The vesting schedule of 48 months is a common practice to ensure long-term commitment from the executive.

Stakeholder Impact

• The stock option grant could potentially dilute existing shareholders' equity if the options are exercised.
• The grant incentivizes the executive to work towards increasing shareholder value.

Key Dates

Keywords

Form 4, stock options, insider trading, Korro Bio, KRRO, Oliver Dolan, executive compensation